ALK and renal cell carcinoma: Although evidence for the treatment of ALK-rearranged RCC is still lacking, it is hoped that more clinical trials will be conducted in the future to demonstrate the efficacy of targeted agents for the treatment of patients with ALK-rearranged RCC.